Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$0.82 USD
-0.01 (-1.33%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.80 -0.02 (-2.20%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALGS 0.82 -0.01(-1.33%)
Will ALGS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALGS
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Other News for ALGS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
Aligos Therapeutics mourns passing of advisor Stephen Harrison
Aligos Therapeutics to present data on ALG-097558 at ESCMID
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024